Literature DB >> 2302983

Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii.

J P Buts1, P Bernasconi, J P Vaerman, C Dive.   

Abstract

Saccharomyces boulardii (S.b.) is largely used in Western European countries for the treatment of acute infectious enteritis and antibiotic-induced gastrointestinal disorders. To study the mechanisms of the protective effect of S.b. against enteral pathogen infection, we assessed the response of the intestinal secretion of secretory IgA (s-IgA) and of the secretory component of immunoglobulins (SC) to oral administration of high doses (0.5 mg/g body weight, three times per day) of S.b. cells in growing rats. S.b. cells (biological activity: 2.8 x 10(9) viable cells/100 mg) were administered daily by gastric intubation to weanling rats from day 14 until day 22 postpartum. Control groups received either 0.9% saline or ovalbumin following the same schedule. Expressed per milligram of cell protein, SC content was significantly increased in crypt cells isolated from the jejunum (48.5% vs saline controls, P less than 0.05) as it was in the duodenal fluid (62.8% vs saline controls, P less than 0.01) of rats treated with S.b. Oral treatment with S.b. had no effect on the secretion of SC by the liver. In the duodenal fluid of rats treated with S.b. cells, the mean concentration of s-IgA was increased by 56.9% (P less than 0.01) over the concentration of s-IgA measured in saline controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2302983     DOI: 10.1007/bf01536771

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  [Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii].

Authors:  P Chapoy
Journal:  Ann Pediatr (Paris)       Date:  1985-06

2.  Mucosal immunity: The origin and migration patterns of cells in the secretory system.

Authors:  T B Tomasi; L Larson; S Challacombe; P McNabb
Journal:  J Allergy Clin Immunol       Date:  1980-01       Impact factor: 10.793

Review 3.  Transport models for secretory IgA and secretory IgM.

Authors:  P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1981-05       Impact factor: 4.330

4.  [Protection by Saccharomyces boulardii against Escherichia coli diarrhea in newborn mice].

Authors:  J Massot; M Desconclois; J Astoin
Journal:  Ann Pharm Fr       Date:  1983-02

5.  Receptor-mediated transcellular transport of immunoglobulin: synthesis of secretory component as multiple and larger transmembrane forms.

Authors:  K E Mostov; J P Kraehenbuhl; G Blobel
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

6.  A solid phase, direct competition, radioimmunoassay for quantitation of secretory IgA in human serum.

Authors:  D L Delacroix; J P Vaerman
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

7.  Secretory component (SC): preferential binding to heavy (greater than 11S) IgA polymers and IgM in serum, in contrast to predominance of 11S and free SC forms in secretions.

Authors:  D L Delacroix; J P Vaerman
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

8.  Immune responses of rats to live Vibrio cholerae: secretion of antibodies in bile.

Authors:  G D Jackson; G N Cooper
Journal:  Parasite Immunol       Date:  1981       Impact factor: 2.280

9.  Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii.

Authors:  R D Toothaker; G W Elmer
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Role of dietary protein adaptation at weaning in the development of the rat gastrointestinal tract.

Authors:  J P Buts; M Nyakabasa
Journal:  Pediatr Res       Date:  1985-08       Impact factor: 3.756

View more
  38 in total

1.  PCR primers that amplify fungal rRNA genes from environmental samples.

Authors:  J Borneman; R J Hartin
Journal:  Appl Environ Microbiol       Date:  2000-10       Impact factor: 4.792

2.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 3.  Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives.

Authors:  Jean-Paul Buts
Journal:  Dig Dis Sci       Date:  2008-06-05       Impact factor: 3.199

4.  Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.

Authors:  I Castagliuolo; M F Riegler; L Valenick; J T LaMont; C Pothoulakis
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

5.  Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells.

Authors:  D Czerucka; S Dahan; B Mograbi; B Rossi; P Rampal
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

6.  Management of Clostridium difficile Infection.

Authors:  Layth S Al-Jashaami; Herbert L DuPont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

Review 7.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 8.  Effects of Saccharomyces boulardii on intestinal mucosa.

Authors:  Jean-Paul Buts; Nadine De Keyser
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

9.  Studies on the time course of the effects of the probiotic yeast Saccharomyces boulardii on electrolyte transport in pig jejunum.

Authors:  B Schroeder; C Winckler; K Failing; G Breves
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 10.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.